EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action
Marinomed Biotech AG: Binding Term Sheet for the intended issuance of a
convertible bond to the European Investment Bank (EIB) signed
27-Nov-2024 / 13:34 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
Group AG.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Korneuburg, Austria, 27. November 2024 - Marinomed Biotech AG (the
“Company”) announces that it has signed a binding term sheet with the
European Investment Bank (EIB) for the intended issuance of a convertible
bond (registered bond in the name or order) with a nominal value of EUR
423,840, which is to be subscribed exclusively by the European Investment
Bank (EIB) (excluding the statutory subscription rights of existing
shareholders) against the contribution of a right of segregation. The
convertible bond will evidence a conversion right in initially up to
84,768 shares of the Company at a conversion price of EUR 5 per share and
will be issued in December 2024. In the event of conversion of the
convertible bond, it is intended to issue the shares available from the
conditional capital of the Company. A corresponding report on the planned
exclusion of the statutory subscription rights of existing shareholders to
convertible bonds will be published shortly. The required resolution of
the Supervisory Board on the issuance of the convertible bond with the
exclusion of subscription rights can be adopted at the earliest two weeks
after publication of the report. The necessary consent of the insolvency
administrator for the issuance of the convertible bond has not yet been
obtained.
+++ End of ad-hoc announcement +++
End of Inside Information
══════════════════════════════════════════════════════════════════════════
27-Nov-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2039579
End of Announcement EQS News Service
2039579 27-Nov-2024 CET/CEST
